Non‐invasive candidate protein signature predicts hepatic venous pressure gradient reduction in cirrhotic patients after sustained virologic response
Open Access
- 13 July 2023
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 43 (9) , 1984-1994
Abstract
Background and Aims: A reduction in hepatic venous pressure gradient (HVPG) is the most accurate marker for assessing the severity of portal hypertension and the effectiveness of intervention treatments. This study aimed to evaluate the prognostic potential of blood‐based proteomic biomarkers in predicting HVPG response amongst cirrhotic patients with portal hypertension due to Hepatitis C virus (HCV) and had achieved sustained virologic response (SVR).Methods: The study comprised 59 patients from two cohorts. Patients underwent paired HVPG (pretreatment and after SVR), liver stiffness (LSM), and enhanced liver fibrosis scores (ELF) measurements, as well as proteomics‐based profiling on serum samples using SomaScan® at baseline (BL) and after SVR (EOS). Machine learning with feature selection (Caret, Random Forest and RPART) methods were performed to determine the proteins capable of classifying HVPG responders. Model performance was evaluated using AUROC (pROC R package).Results: Patients were stratified by a change in HVPG (EOS vs. BL) into responders (greater than 20% decline in HVPG from BL, or 10 mmHg at BL) and non‐responders. LSM and ELF decreased markedly after SVR but did not correlate with HVPG response. SomaScan (SomaLogic, Inc., Boulder, CO) analysis revealed a substantial shift in the peripheral proteome composition, reflected by 82 significantly differentially abundant proteins. Twelve proteins accurately distinguished responders from non‐responders, with an AUROC of .86, sensitivity of 83%, specificity of 83%, accuracy of 83%, PPV of 83%, and NPV of 83%.Conclusions: A combined non‐invasive soluble protein signature was identified, capable of accurately predicting HVPG response in HCV liver cirrhosis patients after achieving SVR.Keywords
Funding Information
- Novartis Institutes for BioMedical Research
This publication has 41 references indexed in Scilit:
- Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targetsProceedings of the National Academy of Sciences, 2012
- From SOMAmer-Based Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamlined Multiplex Proteomic AssayPLOS ONE, 2011
- Aptamer-Based Multiplexed Proteomic Technology for Biomarker DiscoveryPLOS ONE, 2010
- Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertensionJournal of Hepatology, 2009
- Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: Comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scoresJournal of Hepatology, 2009
- Liver cirrhosisThe Lancet, 2008
- Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated CirrhosisGastroenterology, 2007
- Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray ExperimentsStatistical Applications in Genetics and Molecular Biology, 2004
- Interferon for acute hepatitis CCochrane Database of Systematic Reviews, 2001
- Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: A 10-year prospective studyGastroenterology, 1996